biricodar   Click here for help

GtoPdb Ligand ID: 11741

Synonyms: Incel® | VX-710 | VX710
Compound class: Synthetic organic
Comment: Biricodar (VX-710) acts as an inhibitor of the ABCB1 and ABCC1 transporters (a.k.a. P-glycoprotein and multidrug resistance protein 1 respectively) [2]. It restores sensitivity to chemotherapeutic agents in cancer cells that use these efflux pumps to induce drug resistance. Biricodar was developed as an adjunct to chemotherapeutic drugs, for potential in cancer therapy, but it was never apporved for clinical use.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 17
Topological polar surface area 117.15
Molecular weight 603.29
XLogP 4.03
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(cc(c1OC)OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)OC(CCCc1cccnc1)CCCc1cccnc1
Isomeric SMILES COc1cc(cc(c1OC)OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)OC(CCCc1cnccc1)CCCc1cnccc1
InChI InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1
InChI Key CGVWPQOFHSAKRR-NDEPHWFRSA-N
No information available.
Summary of Clinical Use Click here for help
Biricodar (VX-710) was advanced to clinical evaluation, but development was discontinued because VX-710 failed to significantly improve the efficacy of doxorubicin + vincristine in cancer patients with recurrent small cell lung cancer (SCLC) in a Phase 2 study [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00003847 VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer Phase 2 Interventional Vertex Pharmaceuticals Incorporated 1